FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Brian Smith

Research Profile

Living Beings

Concepts & Ideas

Biological Availability

Procedures

Chemicals & Drugs

Phenomena

Species Specificity

Physiology

Anatomy

Osteoclasts

Co-author Network

Publications

TOP 3
Robert W Marquis; Amparo M Lago; James F Callahan; Attiq Rahman; Xiaoyang Dong; George B Stroup; Sandra Hoffman; Maxine Gowen; Eric G DelMar; Bradford C Van Wagenen; Sarah Logan; Scott Shimizu; John Fox; Edward F Nemeth; Theresa Roethke; Brian R Smith; Keith W Ward; Pradip Bhatnagar
Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.
Robert W Marquis; Amparo M Lago; James F Callahan; Robert E Lee Trout; Maxine Gowen; Eric G DelMar; Bradford C Van Wagenen; Sarah Logan; Scott Shimizu; John Fox; Edward F Nemeth; Zheng Yang; Theresa Roethke; Brian R Smith; Keith W Ward; John Lee; Richard M Keenan; Pradip Bhatnagar
Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.
Keith W Ward; Brian R Smith
A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Brian Smith (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Robert W Marquis; Amparo M Lago; James F Callahan; Attiq Rahman; Xiaoyang Dong; George B Stroup; Sandra Hoffman; Maxine Gowen; Eric G DelMar; Bradford C Van Wagenen; Sarah Logan; Scott Shimizu; John Fox; Edward F Nemeth; Theresa Roethke; Brian R Smith; Keith W Ward; Pradip Bhatnagar
Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.
Journal of medicinal chemistry 2009;52(21):6599-605.
2009: Robert W Marquis; Amparo M Lago; James F Callahan; Robert E Lee Trout; Maxine Gowen; Eric G DelMar; Bradford C Van Wagenen; Sarah Logan; Scott Shimizu; John Fox; Edward F Nemeth; Zheng Yang; Theresa Roethke; Brian R Smith; Keith W Ward; John Lee; Richard M Keenan; Pradip Bhatnagar
Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.
Journal of medicinal chemistry 2009;52(13):3982-93.
2004: Keith W Ward; Brian R Smith
A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(6):612-9.
2004: Keith W Ward; Brian R Smith
A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(6):603-11.
2004: Keith W Ward; L B Hardy; J R Kehler; Leonard M Azzarano; Brian R Smith
Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion.
Xenobiotica; the fate of foreign compounds in biological systems 2004;34(4):367-77.
2004: Keith W Ward; Leonard M Azzarano; C A Evans; Brian R Smith
Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations.
Xenobiotica; the fate of foreign compounds in biological systems 2004;34(4):353-66.
2004: Keith W Ward; Gary J Stelman; Jayme A Morgan; Kelli S Zeigler; Leonard M Azzarano; Jonathan R Kehler; Jeanelle E McSurdy-Freed; Joel W Proksch; Brian R Smith
Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(2):172-7.
2004: Robert W Marquis; Keith W Ward; Theresa J Roethke; Brian R Smith; Yu Ru; Dennis S Yamashita; Thaddeus Tomaszek; Peter D Gorycki; H Y Cheng; Ian E James; George B Stroup; Michael W Lark; Maxine Gowen; Daniel F Veber
An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.
Molecular pharmaceutics 2004;1(1):97-100.
2003: William H Miller; Peter J Manley; Russell D Cousins; Karl F Erhard; Dirk A Heerding; Chet Kwon; Stephen T Ross; James Samanen; Dennis T Takata; Irene N Uzinskas; Catherine C K Yuan; R Curtis Haltiwanger; Catherine J Gress; Michael W Lark; Shing-Mei Hwang; Ian E James; David J Rieman; Robert N Willette; Tian-Li Yue; Leonard M Azzarano; Kevin L Salyers; Brian R Smith; Keith W Ward; Kyung O Johanson; William F Huffman
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Bioorganic & medicinal chemistry letters 2003;13(8):1483-6.
2003: Cherng-Yih Perng; Albert S Kearney; Nagesh R Palepu; Brian R Smith; Leonard M Azzarano
Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens.
International journal of pharmaceutics 2003;250(1):147-56.
2002: Keith W Ward; Leonard M Azzarano; Jayme A Morgan; Michael J Gould; Cherng-Yih Perng; Pamela R Souder; David Lundberg; Brian R Smith
Pharmacokinetics of SB-247083, a potent and selective endothelin(A) receptor antagonist, in the rat, dog, and monkey.
Biopharmaceutics & drug disposition 2002;23(8):339-49.
2002: Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple
Molecular properties that influence the oral bioavailability of drug candidates.
Journal of medicinal chemistry 2002;45(12):2615-23.
2002: Michael W Lark; George B Stroup; Ian E James; RA Dodds; Shing-Mei Hwang; Simon M Blake; BA Lechowska; Sandra J Hoffman; Brian R Smith; RD Kapadia; X Liang; Karl F Erhard; Yu Ru; X Dong; Robert W Marquis; Daniel F Veber; Maxine Gowen
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Bone 2002;30(5):746-53.
2002: Keith W Ward; Joel W Proksch; Peter D Gorycki; C P Yu; M Y Ho; B D Bush; Mark A Levy; Brian R Smith
SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man.
Xenobiotica; the fate of foreign compounds in biological systems 2002;32(3):235-50.
2002: Keith W Ward; Joel W Proksch; Kevin L Salyers; Leonard M Azzarano; Jayme A Morgan; Theresa J Roethke; Jeanelle E McSurdy-Freed; Mark A Levy; Brian R Smith
SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics.
Xenobiotica; the fate of foreign compounds in biological systems 2002;32(3):221-33.
2001: Keith W Ward; J W Prokscht; L M Azzaranot; J A Mumawa; Theresa J Roethke; Gary J Stelman; M J Walsh; K S Zeigler; Jeanelle E McSurdy-Freed; J R Kehlert; J Chokshi; Mark A Levy; Brian R Smith
Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase.
Xenobiotica; the fate of foreign compounds in biological systems 2001;31(11):783-97.
2001: George B Stroup; Michael W Lark; Daniel F Veber; A Bhattacharyya; Simon Blake; LC Dare; Karl F Erhard; Sandra J Hoffman; Ian E James; Robert W Marquis; Yu Ru; Janice Vasko-Moser; Brian R Smith; Thaddeus Tomaszek; Maxine Gowen
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2001;16(10):1739-46.
2001: Keith W Ward; Joel W Proksch; Leonard M Azzarano; Kevin L Salyers; Jeanelle E McSurdy-Freed; T M Molnar; Mark A Levy; Brian R Smith
SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.
Pharmaceutical research 2001;18(9):1336-44.
2001: Michael W Lark; George B Stroup; RA Dodds; RD Kapadia; Sandra J Hoffman; Shing-Mei Hwang; Ian E James; BA Lechowska; X Liang; David J Rieman; Kevin L Salyers; K Ward; Brian R Smith; William H Miller; William F Huffman; Maxine Gowen
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2001;16(2):319-27.
2001: Keith W Ward; Joel W Proksch; Mark A Levy; Brian R Smith
Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(1):82-8.
2000: Maxine Gowen; George B Stroup; RA Dodds; Ian E James; Bartholomew Votta; Brian R Smith; Pradip Bhatnagar; A M Lago; James F Callahan; EG DelMar; MA Miller; Edward F Nemeth; John Fox
Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.
The Journal of clinical investigation 2000;105(11):1595-604.
2000: Keith W Ward; R Griffiths; Mark A Levy; Brian R Smith
Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity.
The Journal of pharmacology and experimental therapeutics 2000;293(2):468-79.
1999: Keith W Ward; Leonard M Azzarano; WE Bondinell; Russell D Cousins; William F Huffman; Dalia R Jakas; Richard M Keenan; Thomas W Ku; David Lundberg; William H Miller; J A Mumaw; Kenneth A Newlander; J L Pirhalla; Theresa J Roethke; Kevin L Salyers; P R Souder; Gary J Stelman; Brian R Smith
Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(11):1232-41.
1999: Michael W Lark; George B Stroup; Shing-Mei Hwang; Ian E James; David J Rieman; FH Drake; JN Bradbeer; A Mathur; Karl F Erhard; Kenneth A Newlander; Stephen T Ross; Kevin L Salyers; Brian R Smith; William H Miller; William F Huffman; Maxine Gowen
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
The Journal of pharmacology and experimental therapeutics 1999;291(2):612-7.
1999: Richard M Keenan; William H Miller; L S Barton; WE Bondinell; Russell D Cousins; D F Eppley; Shing-Mei Hwang; Chet Kwon; MA Lago; TT Nguyen; Brian R Smith; Irene N Uzinskas; Catherine C K Yuan
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.
Bioorganic & medicinal chemistry letters 1999;9(13):1801-6.
1998: Richard M Keenan; MA Lago; William H Miller; FE Ali; Russell D Cousins; L B Hall; Shing-Mei Hwang; Dalia R Jakas; Chet Kwon; CS Louden; TT Nguyen; Eliot ohlstein; David J Rieman; Stephen T Ross; James Samanen; Brian R Smith; JM Stadel; Dennis T Takata; L Vickery; Catherine C K Yuan; Tian-Li Yue
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.
Bioorganic & medicinal chemistry letters 1998;8(22):3171-6.
1998: Richard M Keenan; William H Miller; MA Lago; FE Ali; WE Bondinell; James F Callahan; RR Calvo; Russell D Cousins; Shing-Mei Hwang; Dalia R Jakas; Thomas W Ku; Chet Kwon; TT Nguyen; V A Reader; David J Rieman; Stephen T Ross; Dennis T Takata; Irene N Uzinskas; Catherine C K Yuan; Brian R Smith
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Bioorganic & medicinal chemistry letters 1998;8(22):3165-70.